Cellulose Sponge, the Detector of Esophageal Cancer: Innovation for Early Detection of Esophageal Cancer without Biopsy?: A Mini Review

Nurul Hidayah; Yuna Annisa Salsabila

doi:10.3889/oamjms.2022.9142

Authors

Nurul hidayah Department of Nursing, Poltekkes Kemenkes Malang, Malang, Indonesia
Yuna Annisa Salsabila Department of Medical, Medical Faculty, Jember University, Jember Regency, Indonesia https://orcid.org/0000-0002-5977-5332

DOI:

https://doi.org/10.3889/oamjms.2022.9142

Keywords:

Cellulose sponge, Esophageal cancer, Screening

Abstract

Patients with esophageal cancer each year can reach 400,000 people. Inefficient screening methods and worsening symptoms, patients often come late. Squamous cell carcinoma, which is the cause of esophageal cancer, has percentage of 84% of all cancer incidences. So far, the current screening strategy is endoscopy with biopsy. This screening has the main side effect of bleeding in metaplastic area. Cellulose Sponge, the Detector of Esophageal Cancer (CaSPER), can be used for screening without a biopsy using a cellulose sponge. The method used in this mini review is an evidence-based method that focuses on evaluating pre-existing journals. The result is that CaSPER is able to provide strong cellular results of 98%, specificity of 100%, and sensitivity of 97%. Capsules made of glucose and cytosponge of cellulose will bring the metaplastic cells to the sponge. This screening is feasible, safe, comfortable, and without side effects. Using trefoil factor 3 as biomarker is able to distinguish between goblet and pseudogoblet cells. CaSPER is minimally invasive, cheaper, and easily accepted, so that in the future it is hoped that it can be mass produced, especially for areas with high esophageal cancer.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Statistics for Esophageal Cancer | Esophageal Cancer Stats. Available from: https://www.cancer.org/cancer/esophaguscancer/about/key-statistics.html. [Last accessed on 2022 Feb 24].

Rawla P, Barsouk A. Epidemiology of gastric cancer: Global trends, risk factors and prevention. Prz Gastroenterol. 2019;14(1):26. https://doi.org/10.5114/pg.2018.80001 PMid:30944675 DOI: https://doi.org/10.5114/pg.2018.80001

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49. https://doi.org/10.3322/caac.21660 PMid:33538338 DOI: https://doi.org/10.3322/caac.21660

Vaughan TL, Fitzgerald RC. Precision cancer prevention of esophageal adenocarcinoma: A lesson from napoleon. Nat Rev Gastroenterol Hepatol. 2015;12(4):243. DOI: https://doi.org/10.1038/nrgastro.2015.24

Jung HK, Tae CH, Lee HA, Lee H, Choi KD, Park JC, et al. Treatment pattern and overall survival in esophageal cancer during a 13-year period: A nationwide cohort study of 6,354 Korean patients. PLoS One. 2020;15(4):e0231456. https://doi.org/10.1371/journal.pone.0231456 PMid:32275699 DOI: https://doi.org/10.1371/journal.pone.0231456

Hou H, Meng Z, Zhao X, Ding G, Sun M, Wang W, et al. Survival of esophageal cancer in China: A pooled analysis on hospitalbased studies from 2000 to 2018. Front Oncol. 2019;9:548. https://doi.org/10.3389/fonc.2019.00548 PMid:31316913 DOI: https://doi.org/10.3389/fonc.2019.00548

Yang CS, Chen X, Tu S. Etiology and prevention of esophageal cancer. Gastrointest Tumors. 2016;3(1):3-16. https://doi.org/10.1159/000443155 PMid:27722152 DOI: https://doi.org/10.1159/000443155

Shaheen NJ, Falk GW, Iyer PG, Gerson LB. ACG clinical guideline: Diagnosis and management of Barrett’s esophagus. Am J Gastroenterol. 2016;111(1):30-50. https://doi.org/10.1038/ajg.2015.322 PMid:26526079 DOI: https://doi.org/10.1038/ajg.2015.322

Sigmon DF, Fatima S. Fine Needle Aspiration. Treasure Island, FL: StatPearls; 2021.

Middleton DR, Mmbaga BT, O’Donovan M, Abedi-Ardekani B, Debiram-Beecham I, Nyakunga-Maro G, et al. Minimally invasive esophageal sponge cytology sampling is feasible in a Tanzanian community setting. Int J Cancer. 2021;148(5):1208-18. https://doi.org/10.1002/ijc.33366 PMid:33128785 DOI: https://doi.org/10.1002/ijc.33366

Roshandel G, Merat S, Sotoudeh M, Khoshnia M, Poustchi H, Lao-Sirieix P, et al. Pilot study of cytological testing for oesophageal squamous cell dysplasia in a high-risk area in Northern Iran. Br J Cancer. 2014;111(12):2235-41. https://doi.org/10.1038/bjc.2014.506 PMid:25247319 DOI: https://doi.org/10.1038/bjc.2014.506

Fitzgerald RC, di Pietro M, O’Donovan M, Maroni R, Muldrew B, Debiram-Beecham I, et al. Cytosponge-trefoil factor 3 versus usual care to identify Barrett’s oesophagus in a primary care setting: A multicentre, pragmatic, randomised controlled trial. Lancet. 2020;396(10247):333-44. https://doi.org/10.1016/S0140-6736(20)31099-0 PMid:32738955 DOI: https://doi.org/10.1016/S0140-6736(20)31099-0

“Sponge on a String” Test for Esophageal Cancer shows Promise - Mayo Clinic Cancer Center’s Online Magazine – Mayo Clinic Research. Available from: https://www.mayo.edu/research/forefront/sponge-on-a-string-test-for-esophagealcancer-shows-promise. [Last accessed on 2022 Feb 24].

Swart N, Maroni R, Muldrew B, Sasieni P, Fitzgerald RC, Morris S. Economic evaluation of Cytosponge®-trefoil factor 3 for Barrett esophagus: A cost-utility analysis of randomised controlled trial data. EClinicalMedicine. 2021;37:100969. DOI: https://doi.org/10.1016/j.eclinm.2021.100969

Sharifi A, Dolatshahi S, Rezaeifar A, Ramim T. Sensitivity and Specificity of Endoscopy in Diagnosis for Barrett’s Esophagus. Tehran University Medical Journal. 2014;72:396-403.

Kadri PS, Lao-Sirieix I, O’Donovan M, Debiram I, Das M, Blazeby JM, et al. Acceptability and accuracy of a nonendoscopic screening test for Barrett’s oesophagus in primary care: Cohort study. BMJ. 2010;341:c4372. https://doi.org/10.1136/bmj.c4372 PMid:20833740 DOI: https://doi.org/10.1136/bmj.c4372

Hao J, Critchley-Thorne R, Diehl DL, Snyder SR. A costeffectiveness analysis of an adenocarcinoma risk prediction multi-biomarker assay for patients with Barrett’s esophagus. Clin Outcomes Res. 2019;11:623-35. https://doi.org/10.2147/CEOR.S221741 PMid:31749626 DOI: https://doi.org/10.2147/CEOR.S221741

Li Q, Wang K, Su C, Fang J. Serum trefoil factor 3 as a protein biomarker for the diagnosis of colorectal cancer. Technol Cancer Res Treat. 2017;16(4):440-5. https://doi.org/10.1177/1533034616674323 PMid:27760866 DOI: https://doi.org/10.1177/1533034616674323

Zhang CX, Wu CT, Xiao L, Tang SH. The diagnostic and clinicopathological value of trefoil factor 3 in patients with gastric cancer: A systematic review and meta-analysis. Biomarkers. 2021;26(2):95-102. https://doi.org/10.1080/1354750X.2020.1871411 PMid:33401971 DOI: https://doi.org/10.1080/1354750X.2020.1871411

Paterson AL, Gehrung M, Fitzgerald RC, O’Donovan M. Role of TFF3 as an adjunct in the diagnosis of Barrett’s esophagus using a minimally invasive esophageal sampling device – The Cytosponge™. Diagn Cytopathol. 2020;48(3):253-64. DOI: https://doi.org/10.1002/dc.24354

Aihara E, Engevik KA, Montrose MH. Trefoil factor peptides and gastrointestinal function. Annu Rev Physiol. 2017;79:357-80. https://doi.org/10.1146/annurev-physiol-021115-105447 PMid:27992733 DOI: https://doi.org/10.1146/annurev-physiol-021115-105447

Pimentel-Nunes P, Libânio D, Marcos-Pinto R, Areia M, Leja M, Esposito G, et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy. 2019;51(4):365-88. https://doi.org/10.1055/a-0859-1883 PMid:30841008 DOI: https://doi.org/10.1055/a-0859-1883

Ross-Innes CS, Debiram-Beecham I, O’Donovan M, Walker E, Varghese S, Lao-Sirieix P, et al. Evaluation of a minimally invasive cell sampling device coupled with assessment of trefoil factor 3 expression for diagnosing Barrett’s esophagus: A multicenter case-control study. PLoS Med. 2015;12(1):e1001780. https://doi.org/10.1371/journal.pmed.1001780 PMid:25634542 DOI: https://doi.org/10.1371/journal.pmed.1001780

Murphy G, McCormack V, Abedi-Ardekani B, Arnold M, Camargo MC, Dar NA, et al. International cancer seminars: A focus on esophageal squamous cell carcinoma. Ann Oncol. 2017;28(9):2086-93. https://doi.org/10.1093/annonc/mdx279 PMid:28911061 DOI: https://doi.org/10.1093/annonc/mdx279